# Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

> **NCT00757237** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 274 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Aztreonam for Inhalation Solution (AZLI)
- **DRUG:** Tobramycin Inhalation Solution (TIS)

## Key facts

- **NCT ID:** NCT00757237
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-11
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2011-07-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00757237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00757237, "Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00757237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*